MANBA p.Val771Phe
c.2311G>T · rs201779762 · VCV347082
Computational evidence
| Protein change | ||
| AlphaMissense | 0.2325 | likely benign |
|---|---|---|
| REVEL | 0.087 | moderately benign-leaning |
| SaProt | LLR -8.99 | tolerated |
| ⇒ AlphaMissense, REVEL and SaProt all call this tolerated. | ||
| Splicing | ||
| SpliceAI | Δ0.32 | acceptor gain · deltas |
| Pangolin | Δ0.21 | gain · loss 0.00 · agrees with SpliceAI · independent |
| Constraint at this position | ||
| Conservation | phyloP -1.1 | GERP -4.9 |
| Regional constraint | o/e 0.97 | unconstrained · MANE · 129 kb · p 0.31 · regional, not allelic |
| Overall | ||
| CADD | 12.55 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
| Ancestry group | Frequency | 1 in |
|---|---|---|
| Ashkenazi Jewishnot grpmax-eligible | 0.317% | 315 |
| Remaining individualsnot grpmax-eligible | 0.0272% | 3,676 |
| African / African-Americangrpmax | 0.00133% | 74,916 |
| European (non-Finnish) | 0.0011% | 90,774 |
| South Asian | 0.0011% | 91,090 |
Ashkenazi Jewish shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- MANBA
- Protein
- p.Val771Phe
- Coding
- c.2311G>T
- MANE Select
- NM_005908
- dbSNP
- rs201779762
- Type
- single nucleotide variant
- Location
- chr4:102634892 (GRCh38)
- Gene constraint
- LOEUF 0.826 · pLI <0.01 (gnomAD)
- Structure
- AlphaFold pLDDT 96.05
- Residue 771
- a UniProt-annotated variant site (in mansb; complete loss of enzyme activity)
Disease context
beta-mannosidosis — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatmentsFor Beta-mannosidosis (Orphanet):
- Inheritance
- Autosomal recessive
- Onset
- Adolescent, Adult, Childhood, Infancy, Neonatal
- Prevalence
- 1-9 / 1 000 000 (Europe)
Similar variants
- MANBA p.Val771Ile Uncertain significance ★ ⚠ same residue
- MANBA c.1112+1G>T Likely pathogenic ★★ same condition
- MANBA c.1231-1G>A Likely pathogenic ★★ same condition
- MANBA c.1704+1G>T Likely pathogenic ★★ same condition
- MANBA c.2158-2A>G Pathogenic ★★ same condition
- MANBA c.273-1G>A Likely pathogenic ★★ same condition
- MANBA c.378+1G>A Likely pathogenic ★★ same condition
- MANBA c.549+1G>A Likely pathogenic ★★ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/manba-p-val771phe (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown